Employing an integrated approach involving bioinformatic analyses from multiple databases, transforming growth factor-beta 2 (TGFB2) was identified as a crucial gene in gemcitabine-resistant PDAC and was significantly associated with poor gemcitabine therapeutic response.
[Oncogene]